サマリー

世界の遺伝子治療市場は、2023年から2030年にかけて18.3%のCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
遺伝子治療の世界市場、ベクタータイプ別（ウイルスベクター、非ウイルスベクター）、方法別（生体外、生体内）、用途別（腫瘍疾患、心血管疾患、感染症、希少疾患、神経疾患、その他の疾患）、エンドユーザー別（がん研究機関、病院、研究機関、その他）、国（アメリカ、カナダ、メキシコ、ドイツ、フランス、英国、イタリア、ロシア、スペイン、オランダ、スイス、ベルギー、トルコ、その他ヨーロッパ、中国、日本、インド、オーストラリア、韓国、シンガポール、マレーシア、タイ、インドネシア、フィリピン、その他アジア太平洋、南アフリカ、その他中東・アフリカ、ブラジル、その他南米） 産業動向と2030年までの予測
遺伝子治療市場の成長に寄与する主な要因として、以下のものが挙げられます：

- 個別化医療の需要の高まり
- 遺伝性疾患の有病率の上昇
- 遺伝子治療の新たなアプローチ

市場のプレーヤー：

世界の遺伝子治療市場の主要な市場関係者は以下の通りです：
- AGCバイオロジックス
- アムジェン社（Amgen, Inc.
- アンジェス社
- バイオジェン
- ブルーバード・バイオ・インク
- ブリストル・マイヤーズ スクイブ・カンパニー
- CHIESI Farmaceutici S.p.A.
- デンドレオン・ファーマシューティカルズLLC
- Enzyvant Therapeutics GmbH
- フェリングB.V.
- ヤンセン・ファーマシューティカルズ・インク（Janssen Pharmaceuticals, Inc.
- カイトファーマ（ギリアド・サイエンシズ・インクの子会社）
- マリンクロッド
- ノバルティスAG
- オーチャード・セラピューティクス・ピーエルシー
- オックスフォード・バイオメディカ
- 上海サンウェイ・バイオテック有限公司 [東芝機械
- シボノ
- スパーク・セラピューティクス社（Spark Therapeutics, Inc.
- ユニキュアNV.

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE GLOBAL GENE THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET END USER COVERAGE GRID 32
2.8 PRODUCT LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 43
4.2 PORTER FIVE ANALYSIS 44
5 UPDATE ON GERMLINE GENE THERAPY 45
5.1 GERMLINE GENE THERAPY 45
6 GLOBAL GENE THERAPY MARKET, MO 46
6.1 DRIVERS 48
6.1.1 NOVEL APPROACHES TO GENE THERAPY 48
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 48
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 49
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 50
6.2 RESTRAINTS 50
6.2.1 HIGH COST OF GENE THERAPY 50
6.2.2 ETHICAL AND SAFETY CONCERNS 51
6.2.3 COMPLEXITY OF GENE THERAPY 51
6.3 OPPORTUNITIES 52
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 52
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 52
6.4 CHALLENGES 53
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 53
6.4.2 LONG-TERM SAFETY AND EFFICACY 53
7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE 54
7.1 OVERVIEW 55
7.2 VIRAL VECTOR 58
7.2.1 ADENOVIRUS 59
7.2.2 RETROVIRUS 59
7.2.3 LENTIVIRUS 59
7.2.4 ADENO-ASSOCIATED VIRUS 59
7.2.5 VACCINIA VIRUS 59
7.2.6 HERPES SIMPLEX VIRUS 59
7.2.7 OTHERS 59
7.3 NON-VIRAL VECTOR 59
7.3.1 LIPOFECTION 60
7.3.2 INJECTION OF NAKED DNA 60
8 GLOBAL GENE THERAPY MARKET, BY METHOD 61
8.1 OVERVIEW 62
8.2 EX-VIVO 65
8.3 IN-VIVO 65
9 GLOBAL GENE THERAPY MARKET, BY APPLICATION 67
9.1 OVERVIEW 68
9.2 ONCOLOGICAL DISORDERS 71
9.3 CARDIOVASCULAR DISEASES 71
9.4 INFECTIOUS DISEASES 72
9.5 RARE DISEASES 73
9.6 NUEROLOGICAL DISORDERS 74
9.7 OTHER DISEASES 75
10 GLOBAL GENE THERAPY MARKET, BY END USER 76
10.1 OVERVIEW 77
10.2 CANCER INSTITUTES 80
10.3 HOSPITALS 80
10.4 RESEARCH INSTITUTES 81
10.5 OTHERS 82
11 GLOBAL GENE THERAPY MARKET, BY REGION 83
11.1 OVERVIEW 84
11.2 NORTH AMERICA 89
11.2.1 U.S. 95
11.2.2 CANADA 97
11.2.3 MEXICO 99
11.3 EUROPE 101
11.3.1 GERMANY 107
11.3.2 FRANCE 109
11.3.3 U.K. 111
11.3.4 ITALY 113
11.3.5 SPAIN 115
11.3.6 RUSSIA 117
11.3.7 TURKEY 119
11.3.8 NETHERLANDS 121
11.3.9 BELGIUM 123
11.3.10 SWITZERLAND 125
11.3.11 REST OF EUROPE 127
11.4 ASIA-PACIFIC 128
11.4.1 CHINA 134
11.4.2 JAPAN 136
11.4.3 SOUTH KOREA 138
11.4.4 INDIA 140
11.4.5 AUSTRALIA 142
11.4.6 SINGAPORE 144
11.4.7 THAILAND 146
11.4.8 MALAYSIA 148
11.4.9 INDONESIA 150
11.4.10 PHILIPPINES 152
11.4.11 REST OF ASIA-PACIFIC 154
11.5 SOUTH AMERICA 155
11.5.1 BRAZIL 161
11.5.2 REST OF SOUTH AMERICA 163
11.6 MIDDLE EAST AND AFRICA 164
11.6.1 SOUTH AFRICA 170
11.6.2 REST OF MIDDLE EAST AND AFRICA 172
12 GLOBAL GENE THERAPY MARKET, COMPANY LANDSCAPE 173
12.1 COMPANY SHARE ANALYSIS: GLOBAL 173
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 174
12.3 COMPANY SHARE ANALYSIS: EUROPE 175
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 176
13 COMPANY PROFILES 177
13.1 BIOGEN 177
13.1.1 COMPANY SNAPSHOT 177
13.1.2 REVENUE ANALYSIS 177
13.1.3 COMPANY SHARE ANALYSIS 178
13.1.4 SWOT ANALYSIS 178
13.1.5 PRODUCT PORTFOLIO 179
13.1.6 RECENT DEVELOPMENT 179
13.2 KITE PHARMA 180
13.2.1 COMPANY SNAPSHOT 180
13.2.2 REVENUE ANALYSIS 180
13.2.3 COMPANY SHARE ANALYSIS 181
13.2.4 SWOT ANALYSIS 181
13.2.5 PRODUCT PORTFOLIO 182
13.2.6 RECENT DEVELOPMENT 182
13.3 NOVARTIS AG 183
13.3.1 COMPANY SNAPSHOT 183
13.3.2 REVENUE ANALYSIS 183
13.3.3 COMPANY SHARE ANALYSIS 184
13.3.4 SWOT ANALYSIS 184
13.3.5 PRODUCT PORTFOLIO 185
13.3.6 RECENT DEVELOPMENTS 185
13.4 BRISTOL-MYERS SQUIBB COMPANY. 186
13.4.1 COMPANY SNAPSHOT 186
13.4.2 REVENUE ANALYSIS 186
13.4.3 COMPANY SHARE ANALYSIS 187
13.4.4 SWOT ANALYSIS 187
13.4.5 PRODUCT PORTFOLIO 188
13.4.6 RECENT DEVELOPMENT 188
13.5 OXFORD BIOMEDICA 189
13.5.1 COMPANY SNAPSHOT 189
13.5.2 REVENUE ANALYSIS 189
13.5.3 COMPANY SHARE ANALYSIS 190
13.5.4 SWOT ANALYSIS 190
13.5.5 PRODUCT PORTFOLIO 191
13.5.6 RECENT DEVELOPMENTS 191
13.6 AGC BIOLOGICS 192
13.6.1 COMPANY SNAPSHOT 192
13.6.2 PRODUCT PORTFOLIO 192
13.6.3 RECENT DEVELOPMENT 192
13.7 ANGES, INC 193
13.7.1 COMPANY SNAPSHOT 193
13.7.2 REVENUE ANALYSIS 193
13.7.3 PRODUCT PORTFOLIO 194
13.7.4 RECENT DEVELOPMENT 194
13.8 AMGEN INC. 195
13.8.1 COMPANY SNAPSHOT 195
13.8.2 REVENUE ANALYSIS 195
13.8.3 PRODUCT PORTFOLIO 196
13.8.4 RECENT DEVELOPMENT 196
13.9 BLUEBIRD BIO, INC. 197
13.9.1 COMPANY SNAPSHOT 197
13.9.2 PRODUCT PORTFOLIO 197
13.9.3 RECENT DEVELOPMENT 197
13.10 CHIESI FARMACEUTICI S.P.A 198
13.10.1 COMPANY SNAPSHOT 198
13.10.2 REVENUE ANALYSIS 198
13.10.3 PRODUCT PORTFOLIO 199
13.10.4 RECENT DEVELOPMENT 199
13.11 DENDREON PHARMACEUTICALS LLC 200
13.11.1 COMPANY SNAPSHOT 200
13.11.2 PRODUCT PORTFOLIO 200
13.11.3 RECENT DEVELOPMENT 200
13.12 ENZYVANT THERAPEUTICS GMBH 201
13.12.1 COMPANY SNAPSHOT 201
13.12.2 RODUCT PORTFOLIO 201
13.12.3 RECENT DEVELOPMENT 201
13.13 FERRING B.V. 202
13.13.1 COMPANY SNAPSHOT 202
13.13.2 PRODUCT PORTFOLIO 202
13.13.3 RECENT DEVELOPMENT 202
13.14 JANSSEN PHARMACEUTICALS, INC. 203
13.14.1 COMPANY SNAPSHOT 203
13.14.2 PRODUCT PORTFOLIO 203
13.14.3 RECENT DEVELOPMENT 203
13.15 MALLINCKRODT. 204
13.15.1 COMPANY SNAPSHOT 204
13.15.2 REVENUE ANALYSIS 204
13.15.3 PRODUCT PORTFOLIO 205
13.15.4 RECENT DEVELOPMENT 205
13.16 ORCHARD THERAPEUTICS PLC. 206
13.16.1 COMPANY SNAPSHOT 206
13.16.2 REVENUE ANALYSIS 206
13.16.3 PRODUCT PORTFOLIO 207
13.16.4 RECENT DEVELOPMENT 207
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 208
13.17.1 COMPANY SNAPSHOT 208
13.17.2 PRODUCT PORTFOLIO 208
13.17.3 RECENT DEVELOPMENT 208
13.18 SIBONO 209
13.18.1 COMPANY SNAPSHOT 209
13.18.2 PRODUCT PORTFOLIO 209
13.18.3 RECENT DEVELOPMENT 209
13.19 SPARK THERAPEUTICS, INC. 210
13.19.1 COMPANY SNAPSHOT 210
13.19.2 PRODUCT PORTFOLIO 210
13.19.3 RECENT DEVELOPMENT 210
13.20 UNIQURE NV. 211
13.20.1 COMPANY SNAPSHOT 211
13.20.2 REVENUE ANALYSIS 211
13.20.3 PRODUCT PORTFOLIO 212
13.20.4 RECENT DEVELOPMENT 212
14 QUESTIONNAIRE 213
15 RELATED REPORTS 216

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 57
TABLE 2 GLOBAL VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 3 GLOBAL VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 58
TABLE 4 GLOBAL NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 5 GLOBAL NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 60
TABLE 6 GLOBAL GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 64
TABLE 7 GLOBAL EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 8 GLOBAL IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 9 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 70
TABLE 10 GLOBAL ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 11 GLOBAL CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 12 GLOBAL INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 13 GLOBAL RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 14 GLOBAL NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 15 GLOBAL OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 GLOBAL GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 79
TABLE 17 GLOBAL CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 18 GLOBAL HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 19 GLOBAL RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 20 GLOBAL OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 21 GLOBAL GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 93
TABLE 23 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 93
TABLE 24 NORTH AMERICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
TABLE 25 NORTH AMERICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 93
TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 94
TABLE 28 NORTH AMERICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 94
TABLE 29 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 30 U.S. VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 31 U.S. NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 32 U.S. GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 95
TABLE 33 U.S. GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 96
TABLE 34 U.S. GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 96
TABLE 35 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 36 CANADA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 37 CANADA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 38 CANADA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 97
TABLE 39 CANADA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 98
TABLE 40 CANADA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 98
TABLE 41 MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 42 MEXICO VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 43 MEXICO NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 44 MEXICO GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 99
TABLE 45 MEXICO GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 100
TABLE 46 MEXICO GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 100
TABLE 47 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 105
TABLE 48 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 105
TABLE 49 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 50 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 51 EUROPE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 106
TABLE 52 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 106
TABLE 53 EUROPE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 106
TABLE 54 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 107
TABLE 55 GERMANY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 107
TABLE 56 GERMANY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 107
TABLE 57 GERMANY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 107
TABLE 58 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 108
TABLE 59 GERMANY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 108
TABLE 60 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 109
TABLE 61 FRANCE VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 109
TABLE 62 FRANCE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 109
TABLE 63 FRANCE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 109
TABLE 64 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 110
TABLE 65 FRANCE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 110
TABLE 66 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 111
TABLE 67 U.K. VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 111
TABLE 68 U.K. NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 111
TABLE 69 U.K. GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 111
TABLE 70 U.K. GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 112
TABLE 71 U.K. GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 112
TABLE 72 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 113
TABLE 73 ITALY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 113
TABLE 74 ITALY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 113
TABLE 75 ITALY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 113
TABLE 76 ITALY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 114
TABLE 77 ITALY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 114
TABLE 78 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 115
TABLE 79 SPAIN VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 115
TABLE 80 SPAIN NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 115
TABLE 81 SPAIN GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 115
TABLE 82 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 116
TABLE 83 SPAIN GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 116
TABLE 84 RUSSIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 117
TABLE 85 RUSSIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 117
TABLE 86 RUSSIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 117
TABLE 87 RUSSIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 117
TABLE 88 RUSSIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 118
TABLE 89 RUSSIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 118
TABLE 90 TURKEY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 119
TABLE 91 TURKEY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 119
TABLE 92 TURKEY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 119
TABLE 93 TURKEY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 119
TABLE 94 TURKEY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120
TABLE 95 TURKEY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 120
TABLE 96 NETHERLANDS GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 121
TABLE 97 NETHERLANDS VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 121
TABLE 98 NETHERLANDS NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 121
TABLE 99 NETHERLANDS GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 121
TABLE 100 NETHERLANDS GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 122
TABLE 101 NETHERLANDS GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 122
TABLE 102 BELGIUM GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 123
TABLE 103 BELGIUM VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 123
TABLE 104 BELGIUM NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 123
TABLE 105 BELGIUM GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 123
TABLE 106 BELGIUM GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
TABLE 107 BELGIUM GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 124
TABLE 108 SWITZERLAND GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 125
TABLE 109 SWITZERLAND VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 125
TABLE 110 SWITZERLAND NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 125
TABLE 111 SWITZERLAND GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 125
TABLE 112 SWITZERLAND GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 126
TABLE 113 SWITZERLAND GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 126
TABLE 114 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 127
TABLE 115 ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 132
TABLE 116 ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 132
TABLE 117 ASIA-PACIFIC VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 118 ASIA-PACIFIC NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 119 ASIA-PACIFIC GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 133
TABLE 120 ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 133
TABLE 121 ASIA-PACIFIC GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 133
TABLE 122 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 134
TABLE 123 CHINA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 134
TABLE 124 CHINA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 134
TABLE 125 CHINA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 134
TABLE 126 CHINA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 127 CHINA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 128 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 136
TABLE 129 JAPAN VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 136
TABLE 130 JAPAN NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 136
TABLE 131 JAPAN GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 136
TABLE 132 JAPAN GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 137
TABLE 133 JAPAN GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 137
TABLE 134 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 138
TABLE 135 SOUTH KOREA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 138
TABLE 136 SOUTH KOREA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 138
TABLE 137 SOUTH KOREA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 138
TABLE 138 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 139
TABLE 139 SOUTH KOREA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 139
TABLE 140 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 140
TABLE 141 INDIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 140
TABLE 142 INDIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 140
TABLE 143 INDIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 140
TABLE 144 INDIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 141
TABLE 145 INDIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 141
TABLE 146 AUSTRALIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 142
TABLE 147 AUSTRALIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 142
TABLE 148 AUSTRALIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 142
TABLE 149 AUSTRALIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 142
TABLE 150 AUSTRALIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 143
TABLE 151 AUSTRALIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 143
TABLE 152 SINGAPORE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 144
TABLE 153 SINGAPORE VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 144
TABLE 154 SINGAPORE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 144
TABLE 155 SINGAPORE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 144
TABLE 156 SINGAPORE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 145
TABLE 157 SINGAPORE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 145
TABLE 158 THAILAND GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 146
TABLE 159 THAILAND VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 146
TABLE 160 THAILAND NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 146
TABLE 161 THAILAND GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 146
TABLE 162 THAILAND GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 147
TABLE 163 THAILAND GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 164 MALAYSIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 148
TABLE 165 MALAYSIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 148
TABLE 166 MALAYSIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 148
TABLE 167 MALAYSIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 148
TABLE 168 MALAYSIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 149
TABLE 169 MALAYSIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 149
TABLE 170 INDONESIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 150
TABLE 171 INDONESIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 150
TABLE 172 INDONESIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 150
TABLE 173 INDONESIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 150
TABLE 174 INDONESIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
TABLE 175 INDONESIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 151
TABLE 176 PHILIPPINES GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 152
TABLE 177 PHILIPPINES VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 152
TABLE 178 PHILIPPINES NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 152
TABLE 179 PHILIPPINES GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 152
TABLE 180 PHILIPPINES GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 153
TABLE 181 PHILIPPINES GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 153
TABLE 182 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 154
TABLE 183 SOUTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 159
TABLE 184 SOUTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 159
TABLE 185 SOUTH AMERICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 186 SOUTH AMERICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 187 SOUTH AMERICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 159
TABLE 188 SOUTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
TABLE 189 SOUTH AMERICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 160
TABLE 190 BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 191 BRAZIL VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 192 BRAZIL NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 193 BRAZIL GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 161
TABLE 194 BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 162
TABLE 195 BRAZIL GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 162
TABLE 196 REST OF SOUTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 163
TABLE 197 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 168
TABLE 198 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 168
TABLE 199 MIDDLE EAST AND AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 200 MIDDLE EAST AND AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 201 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 169
TABLE 202 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 169
TABLE 203 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 169
TABLE 204 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 170
TABLE 205 SOUTH AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 170
TABLE 206 SOUTH AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 170
TABLE 207 SOUTH AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 170
TABLE 208 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
TABLE 209 SOUTH AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 171
TABLE 210 REST OF MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 172